Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

Gilead’s HIV product sales, which make up the bulk of its revenue, increased 6% YoY to $4.6 billion, but fell 16% ...

building on Gilead's decades of leadership in HIV innovation. In oncology, earlier this week, we announced the positive results from the Phase 3 ASCENT-04 study of Trodelvy, in combination with ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street ...

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell in late action.

Reports Q1 reveue $6.7B, consensus $6.81B. “Gilead (GILD) had a strong start to the year driven by excellent commercial and clinical execution ...

Sanofi signed a deal with Earendil Labs for $125 million upfront and $1.72 billion in milestone payments. Regeneron Pharmaceuticals signed a deal worth more than $3 billion with contract drug ...